Industries > Pharma > Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025
Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025
Prospects for Development, Manufacturing and Business Expansion
Generic Drug Producers – Discover Top Companies’ Revenue Prospects Now, Benefiting Your Influence
What does the future hold for manufacturers and sellers of generic medicines? Visiongain’s new report shows you leading companies’ prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.
For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?
Sales predictions and other data to help you stay ahead in competitive intelligence
In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.
Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.
Assessments of top companies – capabilities, results, competition and sales potentials
Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information:
• Discussion of activities, technologies and recent financial results
• Assessment of developments – mergers and acquisitions (M&A), new products, outlooks, challenges and plans
• Forecasting of generic drug revenues to 2025 (for 19 leading companies).
Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.
For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies’ gross profit margins, EBITDA margins and historical revenue growth.
The following sections show how our new investigation helps your work.
North America – outlooks for leading generic drug producers and sellers
First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms:
• Par Pharmaceuticals.
In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.
Europe – prospects for leading generics players
Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms:
• Novartis (Sandoz)
• Fresenius Kabi
• Gedeon Richter
• Stada Arzneimittel.
The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.
India – analysis of leading generic drug firms
Our new work also assesses 10 Indian generic drug producers, including these firms:
• Sun Pharmaceutical Industries
• Dr. Reddy’s Laboratories
How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.
Producers from the rest of world – assess technologies, progress and prospects
Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies:
• Teva Pharmaceutical Industries
• Aspen Pharmacare
• Abdi Ibrahim
• Sawai Pharmaceuticals.
Countries such as Japan, Brazil and China will become increasingly important for generic drug development, production and sales from 2015 to 2025, our analyses show.
That work explains forces shaping the generics market and industry, helping you explore changes, challenges and opportunities. Discover what the future holds.
Issues affecting generic drug development, manufacturing and sales
Our report discusses issues and events affecting that industry and market from 2015, including these forces:
• Specialty generics – difficult-to-produce medicines with high profit margins
• Shift towards innovative and improved drugs, via expanding R&D budgets
• Mergers and acquisitions (M&A) influencing that expanding healthcare market
• Big pharma firms targeting generics – diversification of product portfolios
• International expansion – targeting developed and developing national markets
• Intellectual property – regulations, challenges and developments
• Biosimilars – opportunities for generic and originator drug companies.
There you explore the generic drug industry’s strengths, weaknesses, opportunities and threats. With our study you discover what the future holds for top generic drug producers.
You also gain our interviews with Sanofi Generics and the Generic Pharmaceutical Association (GPhA). Hear what participants think, say and do, helping you stay ahead.
Ways Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025 – Prospects for Development, Manufacturing and Business Expansion helps
In particular, our new analysis benefits your work in these five main ways:
• Profiles of 43 generics companies – assess product ranges, strategies and sales results, also gaining revenue forecasts to 2025 for 19 organisations
• Competition and opportunities – explore what shapes the generic drugs market’s future, especially companies’ prospects for sustaining and expanding business
• Analysis of what benefits and restrains generic drug makers – assess challenges and strengths, helping you compete and gain advantages
• Reviews of established competitors and rising players in the generics sector – explore needs, competition, technologies and outlooks for future success
• Interviews with authorities – discover what participants in the industry think, say and do, helping you stay ahead in commercial knowledge.
That report, by Visiongain’s in-house analysts in the UK, gives information to benefit your work, saving you hassle and time. You gain data leading companies depend on.
Knowledge found nowhere else, helping your research, analyses and decisions
Our investigation gives independent analysis. You receive competitive intelligence found only in that report, discovering generics companies with the most commercial promise.
With our new survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions. Also find how you can save time and gain in recognition for insight, benefiting your authority.
Predictions for generic drug production and sales – gain by trying our study now
Our new analysis shows you data, trends, opportunities and sales forecasts for top producers and sellers of generic drugs. Avoid missing out – please get our report here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6